DT Investment Partners LLC Sells 241 Shares of Solventum Co. (NYSE:SOLV)

DT Investment Partners LLC lowered its position in Solventum Co. (NYSE:SOLV) by 8.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,695 shares of the company’s stock after selling 241 shares during the quarter. DT Investment Partners LLC’s holdings in Solventum were worth $178,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in SOLV. Hotchkis & Wiley Capital Management LLC bought a new position in shares of Solventum in the third quarter worth $125,488,000. Trian Fund Management L.P. increased its holdings in shares of Solventum by 32.9% in the third quarter. Trian Fund Management L.P. now owns 7,126,255 shares of the company’s stock worth $496,842,000 after purchasing an additional 1,765,676 shares during the period. Point72 Asset Management L.P. bought a new position in shares of Solventum in the third quarter worth $50,948,000. Nordea Investment Management AB increased its holdings in shares of Solventum by 189.5% in the fourth quarter. Nordea Investment Management AB now owns 659,887 shares of the company’s stock worth $43,902,000 after purchasing an additional 431,986 shares during the period. Finally, Assenagon Asset Management S.A. grew its position in Solventum by 4,765.0% in the third quarter. Assenagon Asset Management S.A. now owns 319,628 shares of the company’s stock worth $22,284,000 after acquiring an additional 313,058 shares in the last quarter.

Solventum Price Performance

NYSE SOLV opened at $74.29 on Friday. The company has a 50-day simple moving average of $70.57 and a two-hundred day simple moving average of $68.35. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. Solventum Co. has a 12-month low of $47.16 and a 12-month high of $96.05.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Morgan Stanley upped their target price on shares of Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a research report on Monday, November 11th. Mizuho assumed coverage on shares of Solventum in a research report on Wednesday, December 4th. They issued a “neutral” rating and a $70.00 target price for the company. Finally, Piper Sandler upped their target price on shares of Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a research report on Friday, November 8th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat.com, Solventum has a consensus rating of “Hold” and a consensus target price of $68.29.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.